1.1.1.141 15-hydroxyprostaglandin dehydrogenase (NAD+) breast cancer cell - 700197 1.1.1.141 15-hydroxyprostaglandin dehydrogenase (NAD+) breast cancer cell expression of the enzyme and the estrogen receptor is correlated 668162 1.1.1.145 3beta-hydroxy-DELTA5-steroid dehydrogenase breast cancer cell - 656788, 763397 1.1.1.145 3beta-hydroxy-DELTA5-steroid dehydrogenase breast cancer cell 3beta-hydroxysteroid dehydrogenase type 1 693887 1.1.1.145 3beta-hydroxy-DELTA5-steroid dehydrogenase breast cancer cell isozyme 3beta-HSD1 662371 1.1.1.188 prostaglandin-F synthase breast cancer cell 18fold increase in the median AKR1C3 mRNA levels in breast cancer patients as compared to those without disease 697271 1.1.1.188 prostaglandin-F synthase breast cancer cell of invasive ductal carcinoma of the breast, immunohistochemical analysis 740999 1.1.1.205 IMP dehydrogenase breast cancer cell - 761611 1.1.1.213 3alpha-hydroxysteroid 3-dehydrogenase (Re-specific) breast cancer cell - 675678 1.1.1.27 L-lactate dehydrogenase breast cancer cell - 740255 1.1.1.27 L-lactate dehydrogenase breast cancer cell normal and malignant human breast tissues. The enzyme is highly expressed in breast 740253 1.1.1.270 3beta-hydroxysteroid 3-dehydrogenase breast cancer cell 17beta-HSD7 is amplified in primary and progressive breast cancer 763396 1.1.1.270 3beta-hydroxysteroid 3-dehydrogenase breast cancer cell 3beta-HSD1 is selectively expressed in human placenta, mammary glands and breast tumors in women 763397 1.1.1.270 3beta-hydroxysteroid 3-dehydrogenase breast cancer cell expression of 3beta-hydroxysteroid dehydrogenase type 1 (HSD3B1) in breast cancer is associated with shorter recurrence-free survival, and genetic or pharmacologic inhibition of HSD3B1 reduced colony formation and xenograft growth 763404 1.1.1.270 3beta-hydroxysteroid 3-dehydrogenase breast cancer cell selective expression of 3beta-HSD1 725813 1.1.1.357 3alpha-hydroxysteroid 3-dehydrogenase breast cancer cell - 740017 1.1.1.37 malate dehydrogenase breast cancer cell - 760668 1.1.1.40 malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+) breast cancer cell - 761332 1.1.1.50 3alpha-hydroxysteroid 3-dehydrogenase (Si-specific) breast cancer cell - 740017 1.1.1.51 3(or 17)beta-hydroxysteroid dehydrogenase breast cancer cell - 761900 1.1.1.62 17beta-estradiol 17-dehydrogenase breast cancer cell - 685545, 711649, 713021, 726302, 740542, 740839, 740849, 761756, 761900 1.1.1.62 17beta-estradiol 17-dehydrogenase breast cancer cell 17beta-HSD1 is overexpressed in many breast tumors 688272 1.1.1.62 17beta-estradiol 17-dehydrogenase breast cancer cell the inhibition of the enzyme (17beta-HSD7) constitutes the basis of breast cancer cell proliferation 761756 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) breast cancer cell - 287331 1.11.1.12 phospholipid-hydroperoxide glutathione peroxidase breast cancer cell - 659398 1.13.11.33 arachidonate 15-lipoxygenase breast cancer cell - 676925 1.13.11.53 acireductone dioxygenase (Ni2+-requiring) breast cancer cell - 764226 1.14.11.16 peptide-aspartate beta-dioxygenase breast cancer cell - 742572 1.14.11.16 peptide-aspartate beta-dioxygenase breast cancer cell highly expressed 439254 1.14.11.2 procollagen-proline 4-dioxygenase breast cancer cell P4HA2 mRNA levels are significantly upregulated in breast cancer compared to normal mammary tissue 744594 1.14.11.27 [histone H3]-dimethyl-L-lysine36 demethylase breast cancer cell - 745919 1.14.11.4 procollagen-lysine 5-dioxygenase breast cancer cell - 725955 1.14.11.53 mRNA N6-methyladenine demethylase breast cancer cell - 739559, 765377 1.14.11.65 [histone H3]-dimethyl-L-lysine9 demethylase breast cancer cell - 701223 1.14.11.66 [histone H3]-trimethyl-L-lysine9 demethylase breast cancer cell - 711677, 756531 1.14.11.67 [histone H3]-trimethyl-L-lysine4 demethylase breast cancer cell high expression level of JARID1B 711581 1.14.11.7 procollagen-proline 3-dioxygenase breast cancer cell - 697017 1.14.13.8 flavin-containing monooxygenase breast cancer cell - 673313 1.14.14.18 heme oxygenase (biliverdin-producing) breast cancer cell - 728211 1.14.15.18 calcidiol 1-monooxygenase breast cancer cell - 671357, 695621 1.14.15.18 calcidiol 1-monooxygenase breast cancer cell the enzyme expression is reduced in breast cancer cell specimen compared to healthy breast tissue 672857 1.14.19.17 sphingolipid 4-desaturase breast cancer cell - 744398, 744686 1.15.1.1 superoxide dismutase breast cancer cell harbors MnSOD with the ala16val polymorphism 716197 1.2.1.12 glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) breast cancer cell - 743173 1.2.1.3 aldehyde dehydrogenase (NAD+) breast cancer cell - 697114 1.2.1.31 L-aminoadipate-semialdehyde dehydrogenase breast cancer cell - 675897 1.3.1.1 dihydropyrimidine dehydrogenase (NAD+) breast cancer cell - 686604, 688302, 689367 1.4.3.13 protein-lysine 6-oxidase breast cancer cell - 687920, 713156 1.4.3.13 protein-lysine 6-oxidase breast cancer cell circulating 700903 1.4.3.13 protein-lysine 6-oxidase breast cancer cell hypoxic 697071 1.4.3.13 protein-lysine 6-oxidase breast cancer cell lymph node-negative breast adenocarcinoma cell 685957 1.5.1.2 pyrroline-5-carboxylate reductase breast cancer cell - 762877 1.5.3.13 N1-acetylpolyamine oxidase breast cancer cell - 703028 1.5.3.16 spermine oxidase breast cancer cell - 690800, 711592 1.6.3.1 NAD(P)H oxidase (H2O2-forming) breast cancer cell - 742556 1.8.1.9 thioredoxin-disulfide reductase breast cancer cell - 675915 1.8.3.2 thiol oxidase breast cancer cell expression analysis of a panel of cDNAs derived from 50 clinically-graded normal and malignant breast tissue samples for the expression of QSOX1 mRNAs, significant correlation between relative transcript level and clinical grade malignant breast tumors 743627 2.1.1.100 protein-S-isoprenylcysteine O-methyltransferase breast cancer cell - 704546 2.1.1.17 phosphatidylethanolamine N-methyltransferase breast cancer cell - 697843 2.1.1.220 tRNA (adenine58-N1)-methyltransferase breast cancer cell - 721024 2.1.1.244 protein N-terminal methyltransferase breast cancer cell - 736919 2.1.1.348 mRNA m6A methyltransferase breast cancer cell - 756331 2.1.1.355 [histone H3]-lysine9 N-trimethyltransferase breast cancer cell - 755156 2.1.1.357 [histone H3]-lysine36 N-dimethyltransferase breast cancer cell - 753720 2.1.1.361 [histone H4]-lysine20 N-methyltransferase breast cancer cell - 753133 2.1.1.56 mRNA (guanine-N7)-methyltransferase breast cancer cell - 757896 2.1.1.6 catechol O-methyltransferase breast cancer cell - 658443, 702678 2.1.2.1 glycine hydroxymethyltransferase breast cancer cell expression patterns of SHMT2 in 76 breast cancer patients after modified radical mastectomy, immunohistochemic analysis, SHMT2 is highly expressed in breast cancer cells, and the expression level of SHMT2 is positively correlated with breast cancer grade 736925 2.1.2.2 phosphoribosylglycinamide formyltransferase 1 breast cancer cell - 756648 2.1.2.3 phosphoribosylaminoimidazolecarboxamide formyltransferase breast cancer cell - 756648 2.2.1.1 transketolase breast cancer cell TKTL1 expression in 86% of breast cancer specimens with 45% showing high expression levels 694502 2.3.1.135 phosphatidylcholine-retinol O-acyltransferase breast cancer cell neoplastic and adjacent, non-neoplastic glandular breast tissue specimens from human patients, expression analysis, reduced enzyme expression, LRAT protein progressively decreases with a reduction in the degree of tumor differentiation in invasive breast carcinomas, overview 674069 2.3.1.21 carnitine O-palmitoyltransferase breast cancer cell - 757235 2.3.1.24 sphingosine N-acyltransferase breast cancer cell isozymes CerS2 (EC 2.3.1.297) and CerS6 (EC 2.3.1.24) mRNA is significantly elevated in breast cancer tissue compared to normal tissue, with approximately half of the individuals showing elevated CerS2 and CerS6 mRNA. A significant correlation is found between CerS2 and CerS6 isozyme expression, and between isozymes CerS4 (EC 2.3.1.24) and CerS2/CerS6 expression 752644 2.3.1.291 sphingoid base N-palmitoyltransferase breast cancer cell - 752733 2.3.1.297 very-long-chain ceramide synthase breast cancer cell isozymes CerS2 (EC 2.3.1.297) and CerS6 (EC 2.3.1.24) mRNA is significantly elevated in breast cancer tissue compared to normal tissue, with approximately half of the individuals showing elevated CerS2 and CerS6 mRNA. A significant correlation is found between CerS2 and CerS6 isozyme expression, and between isozymes CerS4 (EC 2.3.1.24) and CerS2/CerS6 expression 752644 2.3.1.45 N-acetylneuraminate 7-O(or 9-O)-acetyltransferase breast cancer cell - 677235 2.3.1.48 histone acetyltransferase breast cancer cell - 703846, 735352, 756658, 756850, 758109 2.3.1.5 arylamine N-acetyltransferase breast cancer cell - 735771, 735849, 756146 2.3.1.5 arylamine N-acetyltransferase breast cancer cell methylation status and the transcriptional activity of NAT1 in breast cancer tissues: methylation of NAT1 gene is identified in 39 of the breast carcinomas (54.2%), 23 normal (76.7%) and 25 benign breast tissue samples (80.6%). Breast cancer tissues show significantly lower methylation rates of the NAT1 promoters than the normal and benign tissues. Cancer tissues show lower methylation density rates than normal and benign breast tissues. Tissues that show aberrant methylation of NAT1 show significantly less mRNA expression compared with the unmethylated cases. 20 cancers from the methylated group show positive staining for the estrogen receptor (ER) (51.3%), while 72.7% from the unmethylated group stain positive 689296 2.3.1.5 arylamine N-acetyltransferase breast cancer cell NAT1 is overexpressed in estrogen receptor-positive breast cancer 686256 2.3.1.5 arylamine N-acetyltransferase breast cancer cell patients with ductal carcinoma 676155 2.3.1.57 diamine N-acetyltransferase breast cancer cell - 756851 2.3.1.57 diamine N-acetyltransferase breast cancer cell in breast tumors, SSAT is increased contributing to an increase in acetylated polyamines 701622 2.3.1.85 fatty-acid synthase system breast cancer cell - 704079, 705999 2.3.1.B43 protein-lysine desuccinylase (NAD+) breast cancer cell - 758247 2.3.1.B46 1-acylglycerophosphatidylinositol O-acyltransferase breast cancer cell - 757632 2.3.2.13 protein-glutamine gamma-glutamyltransferase breast cancer cell MDA-MB-231 (doxorubicin resistant) human breast cancer cell 685934 2.3.2.2 gamma-glutamyltransferase breast cancer cell - 694485 2.4.1.102 beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase breast cancer cell - 759882 2.4.1.150 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase breast cancer cell GCNT2 is overexpressed in highly metastatic breast cancer cell lines. GCNT2 expression is also significantly correlated to the metastatic phenotype in breast tumor samples 758992 2.4.1.152 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase breast cancer cell - 735901 2.4.1.155 alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferase breast cancer cell - 693867 2.4.1.155 alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferase breast cancer cell epithelial and metastatic 758997 2.4.1.212 hyaluronan synthase breast cancer cell - 736064, 736145 2.4.1.222 O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase breast cancer cell manic fringe is highly expressed in claudin-low breast cancer 735881 2.4.1.313 protein O-mannose beta-1,3-N-acetylgalactosaminyltransferase breast cancer cell - 725164 2.4.1.80 ceramide glucosyltransferase breast cancer cell - 722787, 736201 2.4.2.12 nicotinamide phosphoribosyltransferase breast cancer cell - 735872 2.4.2.3 uridine phosphorylase breast cancer cell - 705806 2.4.2.3 uridine phosphorylase breast cancer cell negative correlation between UPase expression and the clinical outcome of breast cancer 673810 2.4.2.30 NAD+ ADP-ribosyltransferase breast cancer cell - 736899 2.4.2.4 thymidine phosphorylase breast cancer cell - 684460, 684466, 686140, 688302, 705495 2.4.3.8 alpha-N-acetylneuraminate alpha-2,8-sialyltransferase breast cancer cell - 736910 2.4.3.8 alpha-N-acetylneuraminate alpha-2,8-sialyltransferase breast cancer cell tissue samples of primary invasive breast cancer cases 699089 2.4.3.9 lactosylceramide alpha-2,3-sialyltransferase breast cancer cell - 702982 2.5.1.60 protein geranylgeranyltransferase type II breast cancer cell - 658377 2.6.1.42 branched-chain-amino-acid transaminase breast cancer cell - 758728 2.6.1.42 branched-chain-amino-acid transaminase breast cancer cell BCATc and BCATm are increased in breast cancer 758657 2.6.1.52 phosphoserine transaminase breast cancer cell immunohistochemical detection, in breast carcinoma PSAT1 expression is significantly associated with poor grade tumors and local relapse 760151 2.6.1.52 phosphoserine transaminase breast cancer cell transcriptional regulators TAZ/YAP activity positively correlates with transaminase expression in breast cancer patients 759123 2.6.1.64 glutamine-phenylpyruvate transaminase breast cancer cell transcriptional regulators TAZ/YAP activity positively correlates with transaminase expression in breast cancer patients 759123 2.7.1.105 6-phosphofructo-2-kinase breast cancer cell - 737973, 760902, 761915 2.7.1.107 diacylglycerol kinase (ATP) breast cancer cell - 761306 2.7.1.127 inositol-trisphosphate 3-kinase breast cancer cell - 760540 2.7.1.137 phosphatidylinositol 3-kinase breast cancer cell - 707976 2.7.1.137 phosphatidylinositol 3-kinase breast cancer cell ER-positive breast cancer cells (UMB-1Ca) are grown as tumors in ovariectomized athymic nude mice 686138 2.7.1.138 ceramide kinase breast cancer cell - 761664 2.7.1.138 ceramide kinase breast cancer cell CERK expression is associated with an increased risk of recurrence in women with breast cancer 737976 2.7.1.138 ceramide kinase breast cancer cell tissue samples of primary invasive breast cancer cases 699089 2.7.1.153 phosphatidylinositol-4,5-bisphosphate 3-kinase breast cancer cell - 707977, 710406 2.7.1.154 phosphatidylinositol-4-phosphate 3-kinase breast cancer cell isozyme PI3K-C2beta is overexpressed in human breast cancer cell lines 739216 2.7.1.183 glycoprotein-mannosyl O6-kinase breast cancer cell - 762066 2.7.1.32 choline kinase breast cancer cell - 671362, 672898, 723311, 759595, 760183 2.7.1.48 uridine/cytidine kinase breast cancer cell analysis of the correlation between UCK2 gene expression and breast cancer survival, overview 759533 2.7.1.67 1-phosphatidylinositol 4-kinase breast cancer cell non-specific infiltrating duct and infiltrating lobular carcinomas 721967 2.7.1.74 deoxycytidine kinase breast cancer cell - 761315 2.7.1.91 sphingosine kinase breast cancer cell - 671356 2.7.1.94 acylglycerol kinase breast cancer cell enzyme overexpression 739046 2.7.10.1 receptor protein-tyrosine kinase breast cancer cell - 490103, 672895, 690303, 690447, 701713 2.7.10.1 receptor protein-tyrosine kinase breast cancer cell EphA2 forms a complex with ErbB2, resulting in enhanced activation of Ras-MAPK signaling and RhoA GTPase 693355 2.7.10.1 receptor protein-tyrosine kinase breast cancer cell overexpression of EGFR-TK 662724 2.7.10.1 receptor protein-tyrosine kinase breast cancer cell overexpression of Her2-receptor 661551 2.7.10.1 receptor protein-tyrosine kinase breast cancer cell overexpression of Ron 690303 2.7.10.2 non-specific protein-tyrosine kinase breast cancer cell - 490442, 490457, 490469, 661457, 662172, 662174, 676266, 691526 2.7.10.2 non-specific protein-tyrosine kinase breast cancer cell breast cancer 490443 2.7.10.2 non-specific protein-tyrosine kinase breast cancer cell breast carcinomas 490594 2.7.10.2 non-specific protein-tyrosine kinase breast cancer cell breast tumours 490596 2.7.10.2 non-specific protein-tyrosine kinase breast cancer cell PYK2 673223 2.7.11.10 IkappaB kinase breast cancer cell - 676886 2.7.11.12 cGMP-dependent protein kinase breast cancer cell - 721503, 723796 2.7.11.13 protein kinase C breast cancer cell shows higher levels of PKCalpha than normal breast tissue 695064 2.7.11.16 G-protein-coupled receptor kinase breast cancer cell - 761893 2.7.11.17 Ca2+/calmodulin-dependent protein kinase breast cancer cell - 664865 2.7.11.17 Ca2+/calmodulin-dependent protein kinase breast cancer cell differential expression of CaM-KI and CaM-KII in cell lines MCF-7 and MCF-10A 664506 2.7.11.18 myosin-light-chain kinase breast cancer cell - 685933, 709713 2.7.11.20 elongation factor 2 kinase breast cancer cell - 721661, 741080, 760810, 761029, 761285 2.7.11.22 cyclin-dependent kinase breast cancer cell - 491470, 665497, 681873, 723656 2.7.11.24 mitogen-activated protein kinase breast cancer cell - 665638 2.7.11.25 mitogen-activated protein kinase kinase kinase breast cancer cell high expression level of MEKK3 665600 2.7.12.2 mitogen-activated protein kinase kinase breast cancer cell impaired expression of MKK4 682214 2.7.2.3 phosphoglycerate kinase breast cancer cell moderate PGK1 expression 682792 2.7.4.14 UMP/CMP kinase breast cancer cell distribution of the enzyme expression in different cancer tissue samples, overview 739700 2.7.7.14 ethanolamine-phosphate cytidylyltransferase breast cancer cell - 693518, 721513 2.7.7.19 polynucleotide adenylyltransferase breast cancer cell - 760831, 762420 2.7.7.43 N-acylneuraminate cytidylyltransferase breast cancer cell - 762081 2.7.7.49 RNA-directed DNA polymerase breast cancer cell - 692248 2.7.7.96 ADP-D-ribose pyrophosphorylase breast cancer cell - 761999, 762060 2.8.2.29 [heparan sulfate]-glucosamine 3-sulfotransferase 2 breast cancer cell - 662996, 761128 2.8.2.30 [heparan sulfate]-glucosamine 3-sulfotransferase 3 breast cancer cell - 739207 2.8.2.30 [heparan sulfate]-glucosamine 3-sulfotransferase 3 breast cancer cell 3-OST3A is epigenetically repressed in all breast cancer cell lines of a panel representative of distinct molecular subgroups, except in human epidermal growth factor receptor 2-positive (HER2+) sloan-kettering breast cancer (SKBR3) cells. Epigenetic mechanisms involved both DNA methylation and histone modifications, producing different repressive chromatin environments depending on the cell molecular signature 762063 2.8.2.4 estrone sulfotransferase breast cancer cell - 671361, 676931, 691170, 691624, 693848, 701710, 701711, 761874 2.8.2.4 estrone sulfotransferase breast cancer cell invasive, postmenopausal women 674994 2.8.2.4 estrone sulfotransferase breast cancer cell preinvasive and invasive cancer cells 674994 2.8.2.4 estrone sulfotransferase breast cancer cell reduced SULT1E1 expression in MCF-7 cells, but elevated SULT1E1 expression in breast tumour tissue, which also exhibits elevated E2 concentrations and increased Nrf2 expression as compared to the surrounding. Nrf2 is an oxidative stress responsive transcription protein, in situ expression analysis, overview 761875 2.8.2.B6 [heparan sulfate]-iuronate 2-sulfotransferase breast cancer cell - 761128 3.1.26.5 ribonuclease P breast cancer cell - 691597 3.1.3.11 fructose-bisphosphatase breast cancer cell - 690771 3.1.3.11 fructose-bisphosphatase breast cancer cell FBP1 is commonly upregulated in tumor tissues compared with non-tumor tissues regardless of histological type 750008 3.1.3.16 protein-serine/threonine phosphatase breast cancer cell elevated levels of PP5 protein occur in human breast cancer and suggest that PP5 over-expression may aid tumor progression 691077 3.1.3.2 acid phosphatase breast cancer cell - 679089 3.1.3.48 protein-tyrosine-phosphatase breast cancer cell - 749498 3.1.3.5 5'-nucleotidase breast cancer cell - 682217, 691078, 693298, 750845 3.1.3.66 phosphatidylinositol-3,4-bisphosphate 4-phosphatase breast cancer cell primary, the enzyme is expressed in nonproliferative estrogen receptor-positive cells in the normal breast, and in estrogen receptor-positive, but not negative, breast cancer cell lines 716766 3.1.3.86 phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase breast cancer cell - 750315, 751180 3.1.31.1 micrococcal nuclease breast cancer cell high SND1 enzyme expression level 729981 3.1.4.2 glycerophosphocholine phosphodiesterase breast cancer cell - 749764 3.1.4.39 alkylglycerophosphoethanolamine phosphodiesterase breast cancer cell - 696397, 703104, 728853 3.1.4.39 alkylglycerophosphoethanolamine phosphodiesterase breast cancer cell overexpression of the enzyme is frequently observed in cancer tissues, such as breast cancer and glioblastoma 728853 3.1.4.46 glycerophosphodiester phosphodiesterase breast cancer cell the isozyme GDPD5 is significantly overexpressed in highly malignant estrogen receptor negative compared to weakly malignant estrogen receptor positive human breast cancer cells and breast tumors from patients, GDPD5 expression in tumors and correlation to choline containing metabolite levels, overview 730482 3.1.6.1 arylsulfatase (type I) breast cancer cell enzyme expression is unaltered in cancer tissue compared to nonmalignant tissue 707966 3.1.6.2 steryl-sulfatase breast cancer cell - 682219, 706776 3.1.6.2 steryl-sulfatase breast cancer cell expression of STS mRNA and STS activity are increased in malignant breast tissues compared with that in non-malignant tissues 656640 3.1.6.2 steryl-sulfatase breast cancer cell hormone-dependent 714821 3.2.1.127 1,6-alpha-L-fucosidase breast cancer cell - 699825 3.2.1.166 heparanase breast cancer cell - 693933, 731867, 732087 3.2.1.166 heparanase breast cancer cell express high levels of endogenous heparanase-1 693320 3.2.1.35 hyaluronoglucosaminidase breast cancer cell - 703231 3.2.1.51 alpha-L-fucosidase breast cancer cell - 699825 3.3.2.11 cholesterol-5,6-oxide hydrolase breast cancer cell enzyme ChEH is upregulated 752861 3.4.11.1 leucyl aminopeptidase breast cancer cell immunohistochemistry analysis of expression levels of LAP3 in breast cancer tissues. Expression of LAP3 in 105 cases of breast cancer is analyzed. The expression rate of LAP3 differs in various pathological histological grades, phenotypes, overview 754242 3.4.11.3 cystinyl aminopeptidase breast cancer cell N-methyl nitrosourea (NMU)-induced breast cancer 753943 3.4.11.9 Xaa-Pro aminopeptidase breast cancer cell - 752870 3.4.13.9 Xaa-Pro dipeptidase breast cancer cell - 700612 3.4.13.9 Xaa-Pro dipeptidase breast cancer cell breast cancer tissue shows high enzyme activity, reduced collagen content and decreased expression of beta1-integrins 683557 3.4.13.9 Xaa-Pro dipeptidase breast cancer cell increased prolidase activity in breast cancer tissue 707010 3.4.14.9 tripeptidyl-peptidase I breast cancer cell - 678513 3.4.18.1 cathepsin X breast cancer cell - 710431 3.4.19.12 ubiquitinyl hydrolase 1 breast cancer cell present in cancerous cells originating from tissues that do not normally express UCH-L1, including pancreatic cancer, colorectal cancer and invasive breast cancer 752715 3.4.19.12 ubiquitinyl hydrolase 1 breast cancer cell UCH-L3 mRNA level is significantly upregulated and UHCL1 mRNA level also show a non-significant increase in breast cancer tissue compared to adjacent normal breast tissue. Both UCH-L1 and UCH-L3 mRNA levels are significantly higher in high histological grade tumors than in low histological grade tumors. UCH-L1 mRNA level in tumors is approximately 10 times higher than that of UCH-L3 679040 3.4.19.9 folate gamma-glutamyl hydrolase breast cancer cell - 683368 3.4.21.106 hepsin breast cancer cell upregulation of hepsin mRNA in estrogen receptor alpha-positive breast tumors compared with estrogen receptor alpha-negative breast tumors 686903 3.4.21.109 matriptase breast cancer cell - 683364, 683489, 683492, 683494, 683763, 683893, 695463, 717902 3.4.21.109 matriptase breast cancer cell strong expression association between matriptase and its substrate prostasin in breast cancer 717902 3.4.21.117 stratum corneum chymotryptic enzyme breast cancer cell - 707996 3.4.21.117 stratum corneum chymotryptic enzyme breast cancer cell enzyme expression analysis in 155 patients, overview 664622 3.4.21.117 stratum corneum chymotryptic enzyme breast cancer cell in contrast to the expression in ovarian cancer, high expression of KLK 7 is strongly associated with good prognosis in breast cancer patients 691153 3.4.21.117 stratum corneum chymotryptic enzyme breast cancer cell lymph node metastasis 707996 3.4.21.35 tissue kallikrein breast cancer cell - 678522, 752895 3.4.21.45 complement factor I breast cancer cell - 753137 3.4.21.59 Tryptase breast cancer cell significantly more tryptase in peritumoral tissue than in normal breast tissue 710170 3.4.21.61 Kexin breast cancer cell - 754945 3.4.21.73 u-Plasminogen activator breast cancer cell - 709912, 710163 3.4.21.75 Furin breast cancer cell - 707598, 708162, 708242, 708753 3.4.21.B25 PACE4 proprotein convertase breast cancer cell - 679039 3.4.21.B28 fibroblast activation protein alpha subunit breast cancer cell - 672907 3.4.21.B28 fibroblast activation protein alpha subunit breast cancer cell FAP-alpha is significantly increased in breast cancer patients with poor outcome and survival 731551 3.4.21.B39 stratum corneum tryptic enzyme breast cancer cell expression levels of KLK5 and KLK7 in benign breast tissues and metastases, and the relationship between KLK5 and KLK7 expression and and clinicopathological factors. mRNA levels of KLK5 and KLK7 in normal breast tissues, benign breast tissues, primary tumors, and lymph node metastases, overview. mRNA levels of KLK5 and KLK7 are both downregulated in breast cancers relative to normal and benign tissues, and downregulated in metastases compared to primary cancers 707996 3.4.21.B39 stratum corneum tryptic enzyme breast cancer cell no expression 670978 3.4.21.B41 kallikrein 10 breast cancer cell - 678524, 678530, 679256 3.4.21.B41 kallikrein 10 breast cancer cell downregulation due to hypermethylation of exon 3 667874 3.4.21.B41 kallikrein 10 breast cancer cell KLK10 is not methylated in normal breast tissues and fibroadenomas while it is in 5 of 10 breast tumors and in 1 of 10 matching normal tissues 690443 3.4.21.B43 kallikrein 12 breast cancer cell - 679276 3.4.21.B43 kallikrein 12 breast cancer cell enzyme splice variant KLK12sv3 is more frequently expressed in tumors of lower grade, early patient TNM stage, and smaller tumor size, overview 732958 3.4.21.B45 kallikrein 14 breast cancer cell KLK14 expression significantly higher compared to normal breast tissues 668103 3.4.21.B6 prostasin breast cancer cell strong expression association between matriptase and its substrate prostasin in breast cancer 717902 3.4.22.1 cathepsin B breast cancer cell - 36625, 753138 3.4.22.15 cathepsin L breast cancer cell - 752936, 755110 3.4.22.26 cancer procoagulant breast cancer cell - 668137 3.4.22.34 Legumain breast cancer cell legumain is overexpressed in the majority of human solid tumours, including breast cancer, colorectal cancer, ovarian cancer, prostate cancer and gastric cancer 752851 3.4.22.38 cathepsin K breast cancer cell biopsy sites, benign lesions, ductal carcinoma in situ, and invasive breast tumors of different stages. Neither epithelial nor stromal expression of CTSK is significantly associated with recurrence-free or overall survival 697375 3.4.22.41 cathepsin F breast cancer cell - 668085 3.4.22.49 separase breast cancer cell increased expression of separase 697382 3.4.22.49 separase breast cancer cell overexpressed in numerous human cancers including breast, bone, brain, and prostate 752903 3.4.22.49 separase breast cancer cell Separase is significantly overexpressed in human breast tumors compared with matched normal tissue (Western blot) 700945 3.4.22.52 calpain-1 breast cancer cell - 710164 3.4.22.53 calpain-2 breast cancer cell - 732050 3.4.22.56 caspase-3 breast cancer cell - 695620, 696872, 697055 3.4.22.56 caspase-3 breast cancer cell a breast cancer Dox resistant MCF-7/Dox cell line 697054 3.4.22.59 caspase-6 breast cancer cell - 647467 3.4.22.59 caspase-6 breast cancer cell invasive operable pT1 and pT2 ductal breast carcinoma are analysed of 210 patients: caspase-6 is overexpressed in 52.9% 680072 3.4.22.61 caspase-8 breast cancer cell - 695620, 697053, 697261 3.4.22.62 caspase-9 breast cancer cell - 717277, 731452 3.4.22.63 caspase-10 breast cancer cell - 710209 3.4.22.B29 calpain 9 breast cancer cell expression analysis 731549 3.4.22.B70 SENP1 peptidase breast cancer cell enzyme SENP1 levels are positively correlated with substrate Pin1 levels in human breast cancer specimens 731577 3.4.22.B71 SENP2 peptidase breast cancer cell weak expression, benign breast adenofibroma cell and malignant breast cancer tissue 732727 3.4.22.B75 SENP7 peptidase breast cancer cell - 731599, 732812 3.4.23.3 gastricsin breast cancer cell - 668809 3.4.23.36 Signal peptidase II breast cancer cell - 754940 3.4.23.5 cathepsin D breast cancer cell - 695419, 695654, 711855, 755627 3.4.23.B24 signal peptide peptidase breast cancer cell high expression level 754940 3.4.24.18 meprin A breast cancer cell - 733064 3.4.24.23 matrilysin breast cancer cell early stage primary cancers, MMP-7 correlates with breast cancer development, overexpression of MMP-7 and ErbB4, overview 683331 3.4.24.35 gelatinase B breast cancer cell - 696965, 708409, 709302, 710245 3.4.24.35 gelatinase B breast cancer cell primary breast tumor cell 696965 3.4.24.56 insulysin breast cancer cell - 683571 3.4.24.7 interstitial collagenase breast cancer cell - 708587, 710246 3.4.24.80 membrane-type matrix metalloproteinase-1 breast cancer cell - 638810, 708543, 754158 3.4.24.82 ADAMTS-4 endopeptidase breast cancer cell - 754958 3.4.24.B10 ADAM12 endopeptidase breast cancer cell - 670445, 719935, 754703, 754704, 755485 3.4.24.B10 ADAM12 endopeptidase breast cancer cell primary breast cancer cell BC1205 755485 3.4.24.B10 ADAM12 endopeptidase breast cancer cell primary breast cancer cell BC1302 755485 3.4.24.B3 matrix metalloproteinase-11 breast cancer cell - 708156, 753930 3.4.24.B3 matrix metalloproteinase-11 breast cancer cell breast tumor tissues display higher expression levels of MMP-11 than the adjacent non-cancerous tissues 708173 3.4.24.B3 matrix metalloproteinase-11 breast cancer cell cancer cell-adipocyte interaction/crosstalk during the initial steps of cancer cell invasion 668150 3.4.24.B3 matrix metalloproteinase-11 breast cancer cell samples from patients with histologically confirmed diagnosis of early invasive breast cancers of ductal types, expression of MMP-11 is increased and more heterogeneous in metastatic specimens compared to non-metastatic tumour samples, quantitative expression and mapping of the cancer biomarker MMP-11 in human breast cancer tissue sections, overview 752463 3.4.24.B4 matrix metalloproteinase-13 breast cancer cell - 691486, 712933 3.4.24.B4 matrix metalloproteinase-13 breast cancer cell expression of MMP13 in tumors 711675 3.4.24.B7 matrix metalloproteinase-26 breast cancer cell elevated MMP-26 expression level 710794 3.5.1.12 biotinidase breast cancer cell analysis of gene expression in breast cancer plasma, diverse tissue samples, profiling, overview 711589 3.5.1.2 glutaminase breast cancer cell - 670391, 694485 3.5.1.23 ceramidase breast cancer cell - 733498 3.5.1.98 histone deacetylase breast cancer cell - 711660 3.5.2.9 5-oxoprolinase (ATP-hydrolysing) breast cancer cell - 694485 3.5.4.4 adenosine deaminase breast cancer cell - 718704 3.5.4.4 adenosine deaminase breast cancer cell the activity of isozyme ADA2 is increased 668272 3.6.1.62 5'-(N7-methylguanosine 5'-triphospho)-[mRNA] hydrolase breast cancer cell - 758325 3.6.4.13 RNA helicase breast cancer cell - 756284 3.6.4.13 RNA helicase breast cancer cell deregulated expression of p68 in breast cancer. The DDX5 locus is consistently strengthened in breast cancer and is usually overexpressed in association with ERBB2. Various breast cancer cell lines exhibit different dependence on DDX5 expression 757299 3.6.4.B10 chaperonin ATPase (protein-folding, protecting from aggregation, protein stabilizing) breast cancer cell - 756668 3.6.5.2 small monomeric GTPase breast cancer cell mRNA levels of RasL10B are down-regulated in all breast cancer cells tested (HBL100, MCF7, MDA-MB-468, MDA-MB-231 and MDA-MB-435. RasL10B) is a member of ras superfamily with tumor suppressor potential 668060 4.1.1.17 ornithine decarboxylase breast cancer cell - 682982, 695299 4.1.1.22 histidine decarboxylase breast cancer cell HDC expression is significantly increased in carcinoma cells 691585 4.1.1.28 aromatic-L-amino-acid decarboxylase breast cancer cell different splicing variants 748845 4.1.1.9 malonyl-CoA decarboxylase breast cancer cell - 706013 4.2.1.11 phosphopyruvate hydratase breast cancer cell - 702980 4.2.1.11 phosphopyruvate hydratase breast cancer cell cell surface ENOA is enhanced 714970 4.3.2.1 argininosuccinate lyase breast cancer cell the enzynme is overexpressed in breast cancer 748794 4.3.2.9 gamma-glutamylcyclotransferase breast cancer cell - 687744, 705761, 720332, 735747 4.4.1.5 lactoylglutathione lyase breast cancer cell MDA-MD-231 cell, JIMT-1 cell 694824 5.1.99.4 alpha-methylacyl-CoA racemase breast cancer cell - 681814, 727322 5.2.1.8 peptidylprolyl isomerase breast cancer cell - 705066 5.3.1.9 glucose-6-phosphate isomerase breast cancer cell - 703022 5.3.3.12 L-dopachrome isomerase breast cancer cell - 748797 5.3.3.8 DELTA3-DELTA2-enoyl-CoA isomerase breast cancer cell - 691485 5.6.2.1 DNA topoisomerase breast cancer cell - 750368 5.6.2.2 DNA topoisomerase (ATP-hydrolysing) breast cancer cell - 693362, 727888 5.6.2.2 DNA topoisomerase (ATP-hydrolysing) breast cancer cell with a mutation in gene BRCA1 691488 6.2.1.15 arachidonate-CoA ligase breast cancer cell a breast cancer cell model, comprising different cell lines, expresses ACSL4 in all cell lines, high expression level 716687 6.3.2.17 tetrahydrofolate synthase breast cancer cell - 745594 6.3.2.2 glutamate-cysteine ligase breast cancer cell - 694485 6.3.2.2 glutamate-cysteine ligase breast cancer cell treatment of human breast cancer cells with 2-deoxy-D-glucose causes metabolic oxidative stress that is accompanied by increases in steady-state levels of glutamate cysteine ligase mRNA, glutamate cysteine ligase activity and glutathione content 672904 6.3.4.3 formate-tetrahydrofolate ligase breast cancer cell high expression level of MTHFD1L 765141 6.4.1.2 acetyl-CoA carboxylase breast cancer cell - 672908, 675919 7.1.2.1 P-type H+-exporting transporter breast cancer cell - 712552 7.1.2.2 H+-transporting two-sector ATPase breast cancer cell - 712552 7.2.2.10 P-type Ca2+ transporter breast cancer cell - 752192 7.6.2.2 ABC-type xenobiotic transporter breast cancer cell - 747044